Press Room

Press Clipping / Sep 09, 2019

The Mark of a Great Company

BITCI News, September 09, 2019

The Mark of a Great Company | Hovione

Pictured above were Gillian Chamberlain, BT with Maarten Schuuruman, MD, HEINEKEN Ireland, Bernard Sheridan, Corporate Affairs Director, Central Bank of Ireland and Paul Downing, General Manager, Hovione.

 

The 2019 Edelman Trust Barometer recently revealed that 75% of Irish people expect CEOs to take the lead on social change issues. Business in the Community Ireland has developed the Business Working Responsibly mark, the only independently audited standard for CSR and Sustainability in Ireland. The Mark can put your CEO and company at the forefront of social change, pioneering best practices in human rights and other social areas, and enabling others to follow suit. To date, 33 of the largest organisations operating in Ireland are certified to the Mark, and testimonials from their CEOs speak to the many benefits associated with certification.

“We want to attract the best talent and having the Mark is a clear demonstration of our responsible business practices and signals to existing and potential staff that we are serious about our corporate social responsibility” – Clive Bellows, Country Head, Northern Trust

 “For our businesses in Ireland, being certified with the Business Working Responsibly Mark helps to convey to employees, customers, local communities and stakeholders that we are fully committed to managing our operations in a socially responsible and sustainable manner “- Oliver Mahon, Senior Vice President – CRH Europe North

So what are some of the benefits of achieving Mark certification?

1. Employee Engagement and Retention

In the last decade the workforce has changed, and with it the culture of the workplace. Together Millennials and Gen Zs make up more than half the world’s population and account for most of the global workforce[1]. This new generation of workers places a much larger focus on social and environmental responsibility. Policies around diversity and inclusion, flexible working and rewards and recognition are being put under the spotlight, as the new workforce wants to work for companies that offer them a socially responsible purpose, without “sacrificing the flexibility to be who they are at work and live a fulfilling life outside of it”[2]. This flexibility doesn’t just mean flexible work hours or locations, but a more inclusive workplace and fair and transparent opportunities for progression.

The Mark takes a focus across all of these workplace indicators and assesses company policies, practices and performance in achieving objectives. Achieving the independently verified certification can enhance your employer brand and help attract and retain employees.

[1] https://www2.deloitte.com/global/en/pages/about-deloitte/articles/mille…

[2] https://www2.deloitte.com/content/dam/Deloitte/us/Documents/about-deloi…

 

2. Customer Relationships

Not only is flexibility in the workplace becoming an essential part of any recruitment package, but so is the impact that a business has on both society and the environment. Research shows that millennials are the most socially conscious generation since the 1960’s[1] and climate change is topping their list of concerns[2] . They are expressing these values both in the demands they make as employees and in the demands they made as consumers. Present day consumers are making socially conscious choices and choosing products that meet their ethical requirements. According to the recent Deloitte Millenial Survey[3], “42% of millennials have begun or deepened a business relationship because they perceive a company’s products or services to have a positive impact on society and/or the environment. Further, 37 percent said they have stopped or lessened a business relationship because of the company’s ethical behaviour.”

The Mark looks at the value chain of companies, and assesses whether their products and service are both socially and environmentally responsible. The certification process also examines the company’s environmental footprint, including waste reduction and carbon emissions amongst much more.

 

3. CEOs as Leaders of Change

Mark certification gives you access to Leaders’ Group on Sustainability, a collaboration between the CEOs of some of Ireland’s largest organisations, addressing pressing social, economic and environmental challenges. This year the Leader’s Group has produced the Low Carbon Pledge, with 49 of Ireland’s largest companies committing to lowering their scope 1&2 emissions by 50% by 2030, and the Social Inclusion Blueprint, a practical guide to create inclusive workplaces and reduce inequality in Ireland.

What does the Mark certification involve?

The Mark can help your company to raise your brand’s CSR profile and better recruit, retain, and engage your employees. Audited by the National Standards Authority of Ireland (NSAI), and based on ISO 26000, The Mark will assess your responsible and sustainable business practices and provide your organisation with an assessment of how well positioned it is to address CSR risks and opportunities in the current business environment. The assessment addresses policies, practices and company performance across five pillars (Governance, Marketplace, Workplace, Environment, and Community which encompass 22 indicators, including Employee Engagement, Responsible Products and Services, Carbon Management and Climate Change Adaptation, and Community Engagement.

Achieving the Mark Certification provides independent verification that will enhance your employer brand, help attract and retain employees, support your corporate responsibility and sustainability credentials and support your organisation in leveraging investment potential.

 

Read article

 

Also in the Press Room

See All

The CDMO is preparing for its New Jersey facility to become fully operational this year. Hovione’s multimillion-dollar investment in expanding its East Windsor, NJ manufacturing site is quickly coming to fruition. Contract Pharma will be visiting the site later in April 2026 to provide a unique overview of what’s new. As a preview, the Contract Pharma team met with Hovione at the Drug, Chemical & Associated Technologies Association (DCAT) Week. David Basile, Vice President of Technical Operations—Americas, spoke at the opening Member Company Announcement Forum on March 23, 2026. In this interview, Basile expands on his remarks at the Announcement Forum. As he explains, Hovione is concentrating not only on New Jersey, but also on facilities in Ireland and Portugal. Contract Pharma: Good manufacturing practice (GMP) operations will soon be fully operational at the New Jersey facility. How has Hovione progressed through this process since the initial investment cycle was announced last fall—or even prior? David Basile: It’s been a really great journey and evolution over the last two to three years, conceiving the plan to grow our U.S. footprint. It was one of the reasons I came aboard with Hovione, to grow that footprint and build our commercial manufacturing prowess in the States. In New Jersey, we had originated [the site] as a tech transfer center. [But] we wanted to grow the organization to be more equivalent with our Portugal and Ireland sites, to do more large-scale manufacturing. So, this is part of that journey. And that’s not just bricks-and-mortar and machinery. It’s been people, talent, partnerships with clients, supporting functions such as QC [quality control] and analytical development. We’re growing our R&D teams as well. It’s a comprehensive approach to systems, people, and processes. CP: At the Member Company Announcement Forum, you ran through some of the major technical specifications of the NJ expansion. Can you talk about a few of the highlights and their capabilities? Basile: This year we’ll be starting up two PSD-3 scale spray dryers. This is a useful scale of machinery for our clients. It plays nicely between the PSD-2 and PSD-4 scales that we have elsewhere in the network. I’d say it’s medium-to-large scale capacity; we could do 30 metric tons annually out of this type of a unit. Product to product, that differs, but we do have products that put that kind of volume out in a PSD-3, so it’s not small-scale. Customers want to hear this because [they want to gain] efficiency with their batch size, and turnaround time. And when we campaign, we can really see significant throughput with this line up of new machinery and assets. The first machine that we will start up is a Hastelloy unit, which is unique. We took a pause [in the construction timeline] to make that upgrade, as we had a client that needed this configuration. There are additional clients that are interested in it too, because you can do acidic solutions and more aggressive kinds of formulations as well as solvent-based formulations. So that’s a unique element of that first machine. The second machine is being qualified later this year. Kind of a twin, but this one is standard 316 stainless steel.  CP: When a company brings a new or expanded facility online, new personnel often accompanies the new tech. What is the workforce addition that you expect, and what are the challenges of retaining top talent? Basile: In preparation for commissioning and startup of this new equipment, we’ve already ramped our headcount up, to be ready for GMP launch. We’ve added roughly 20 employees in preparation for this first machine to go [live]. Over the next 18-plus months, we could see something on a similar scale, getting us up to that 40–50 headcount range for that facility once it’s fully operational—and more later on in 2028, when we bring in the CDC [continuous direct compression] Flex unit. That’s what’s really going to be transformative about this new facility: that integrated offering coming to life. CP: Even if the NJ facility is top of mind right now, let’s also touch on some of your plans in Europe. What is your vision for expanding in Europe in the next two to three years? Basile: Ideally, Hovione’s aim is to build an equivalent manufacturing network, where clients can go to any site across the globe and get a similar breadth and scale of offering. We’re doing that now in Ireland, expanding our PSD-4 scale spray drying. One unit was recently installed. Late last year, it went live. Then there’s at least one other new PSD-4 in motion, which is really exciting, because [spray dryers] at this site were historically [exclusive to] larger chemistry manufacturing for API [active pharmaceutical ingredient] synthesis. So now, they’re further building their muscle with additional large scale spray drying capacity. On the Portugal side, there’s a lot of great things going on. Our Tejo campus, in Seixal, Portugal, is a massive, 4.5-million-square-foot plot of land, and there’s a new, modular facility going up there. It’s incredibly exciting. The design of the facility has been well-thought through with material flows [and] gravity-fed processes. Here, we minimize handling and [maximize] speed of processing. It’s scalable. We call each one of these building segments a finger. You can copy and paste these fingers, and they are built to house both spray drying and drug product assets within each unit. So, why is that relevant? Because we can easily scale the number of fingers. When customers say, “we need more capacity,” we have the design on the table ready to go. We know how to execute, we know how to build and implement our technology platforms in a short timeframe. Deployment timeframes are truly becoming more and more relevant to our clients. CP: From last year’s DCAT Week to this year’s, what conversations are you having with industry colleagues about ever-changing geopolitics? Basile: We’re seeing that local, regional manufacturing capacity is vital. The concept of U.S. for U.S. and China for China seems to be a common theme that our clients are talking about. We happen to have an edge, as we [have already] started our journey of expanding our domestic U.S. capacity. So I think that’s a crucial piece to the puzzle, having dual-sided Atlantic manufacturing operations. The traditional global supply chain model is being challenged. Having soup-to-nuts sites that are fully autonomous in development, scale-up, tech transfer, all the way to commercial scale operation, is vital to Hovione, and how we’re protecting our supply chain. [Concerning] starting raw materials and Tier 2 suppliers, our procurement teams are out in the market making sure that there’s no single point of failure for critical materials [like] polymers and solvents that we utilize. We’re managing and mitigating risk by looking at those secondary suppliers across different geographies. CP: Encapsulating your planned expansions on both sides of the Atlantic, how would you sum up the value to the customer? Basile: It’s about speed-to-market. It’s one partner from early-phase development, clinical scale, all the way through commercial. They gain comfort, trust, and not just capacity and equipment time; it’s also about competency and depth of scientific expertise. We’re not just a traditional CDMO. There’s unique expertise in particle science and spray dried dispersions that we offer our clients that they don’t have. [With] traditional CDMOs, customers typically pay for time in [a particular] unit, for example, they’d say: “I need a machine, and I need [it for] three weeks.” Hovione is truly a partner to our clients. They’re leveraging our platforms, our know-how in spray drying, and our know-how in equipment design. Read the article at ContractPharma.com  

Article

Hovione Eyeing Manufacturing Expansion on Both Sides of Atlantic

Apr 06, 2026

With key expansions coming to fruition on either side of the pond, specialist CDMO Hovione is making sure that drugmakers can access its particle engineering expertise across multiple geographies.  That flexibility will be key for the Portugal-based company in the coming years as the pharmaceutical industry continues to embrace more regional supply chains. In a recent interview, Hovione's David Basile, VP of technical operations for the Americas, discussed this trend and the manufacturer's expansion project, which is set to come online in New Jersey next month.  In the coming weeks, Hovione plans to debut a new spray drying expansion at its campus in East Windsor, New Jersey. The company has invested $100 million to expand its campus, including new construction and the acquisition of an additional facility and greenfield land.  Specifically, one of two pharmaceutical spray drying-3 units, or PSD-3 units, will come online in the coming weeks to tackle amorphous active pharmaceutical ingredients (APIs) and amorphous solid dispersions, according to the company. With some 80% of new small molecules in development insoluble in water, Hovione’s particle engineering and amorphous solid dispersion platform helps medicine developers improve the solubility, bioavailability, and, in some cases, the stability of their drug candidates, Basile said.  The company boasts spray dryers from the lab scale to PSD3 at its original facility in East Windsor, in addition to the pair of large-scale machines about to be activated at the campus' new facility.  “We’re going for a single, unified site with capabilities across the campus to do drug substance through finished drug product under one governance and quality system,” - Basile told Fierce.   Read the full article at FiercePharma.com

Article

As expansions come online, CDMO Hovione aims to meet industry's 'dual supply and sourcing' zeal: exec

Mar 26, 2026